Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193805-24-000619 0001884931 XXXXXXXX LIVE 2 Common Shares, without par value 02/20/2025 true 0001447028 03879J100 Arbutus Biopharma Corp 701 VETERANS CIRCLE WARMINSTER PA 18974 DAVID SALANIC 212-259-4370 WHITEFORT CAPITAL MANAGEMENT, LP 12 East 49th Street, 40th Floor New York NY 10017 JOSEPH KAPLAN 212-259-4370 WHITEFORT CAPITAL MANAGEMENT, LP 12 East 49th Street, 40th Floor New York NY 10017 RYAN NEBEL 212-451-2300 OLSHAN FROME WOLOSKY LLP 1325 Avenue of the Americas New York NY 10019 PATRICIA OLASKER 416-863-0900 DAVIES WARD PHILLIPS & VINEBERG LLP 155 Wellington Street West Toronto A6 M5V 3J7 0001704387 N Whitefort Capital Master Fund, LP WC N E9 0.00 13307967.00 0.00 13307967.00 13307967.00 N 7.0 PN Y Whitefort Capital GP, LLC AF N DE 0.00 13307967.00 0.00 13307967.00 13307967.00 N 7.0 OO 0001884931 N Whitefort Capital Management, LP AF N DE 0.00 13307967.00 0.00 13307967.00 13307967.00 N 7.0 IA PN Y Whitefort Capital Management GP, LLC AF N DE 0.00 13307967.00 0.00 13307967.00 13307967.00 N 7.0 OO Y David Salanic AF N I0 0.00 13307967.00 0.00 13307967.00 13307967.00 N 7.0 IN HC Y Joseph Kaplan AF N X1 0.00 13307967.00 0.00 13307967.00 13307967.00 N 7.0 IN HC Common Shares, without par value Arbutus Biopharma Corp 701 VETERANS CIRCLE WARMINSTER PA 18974 Item 3 is hereby amended and restated to read as follows: The securities of the Issuer purchased by Whitefort Master Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 13,307,967 Shares owned directly by Whitefort Master Fund is approximately $31,535,394, including brokerage commissions. Item 4 is hereby amended to add the following: The Reporting Persons intend to engage in communications with the Issuer, its shareholders and other market participants regarding opportunities to drive shareholder value, including through potential changes to the composition of the Issuer's Board of Directors. Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based upon 189,491,685 Shares outstanding as of November 5, 2024, which is the total number of Shares outstanding as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024. As of the date hereof, Whitefort Master Fund beneficially owns 13,307,967 Shares, constituting approximately 7.0% of the Shares outstanding. Whitefort Master GP, as the general partner of Whitefort Master Fund, may be deemed to beneficially own the 13,307,967 Shares owned by Whitefort Master Fund, constituting approximately 7.0% of the Shares outstanding. Whitefort Management, as the investment manager of Whitefort Master Fund, may be deemed to beneficially own the 13,307,967 Shares owned by Whitefort Master Fund, constituting approximately 7.0% of the Shares outstanding. Whitefort GP, as the general partner of Whitefort Management, may be deemed to beneficially own the 13,307,967 Shares owned by Whitefort Master Fund, constituting approximately 7.0% of the Shares outstanding. Each of Messrs. Salanic and Kaplan, as a Co-Managing Partner of Whitefort Management and a Co-Managing Member of each of Whitefort Master GP and Whitefort GP, may be deemed to beneficially own the 13,307,967 Shares owned by Whitefort Master Fund, constituting approximately 7.0% of the Shares outstanding. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own. Item 5(c) is hereby amended and restated to read as follows: The transactions in securities of the Issuer by the Reporting Persons during the past 60 days are set forth in Exhibit 1 and are incorporated herein by reference. All of such transactions were effected in the open market unless otherwise noted therein. Item 7 is hereby amended to add the following exhibit: 1 - Transactions in Securities. Whitefort Capital Master Fund, LP /s/ David Salanic David Salanic, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner 02/21/2025 /s/ Joseph Kaplan Joseph Kaplan, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner 02/21/2025 Whitefort Capital GP, LLC /s/ David Salanic David Salanic, Co-Managing Member 02/21/2025 /s/ Joseph Kaplan Joseph Kaplan, Co-Managing Member 02/21/2025 Whitefort Capital Management, LP /s/ David Salanic David Salanic, Co-Managing Partner 02/21/2025 /s/ Joseph Kaplan Joseph Kaplan, Co-Managing Partner 02/21/2025 Whitefort Capital Management GP, LLC /s/ David Salanic David Salanic, Co-Managing Member 02/21/2025 /s/ Joseph Kaplan Joseph Kaplan, Co-Managing Member 02/21/2025 David Salanic /s/ David Salanic David Salanic 02/21/2025 Joseph Kaplan /s/ Joseph Kaplan Joseph Kaplan 02/21/2025